These results indicate that serum EphA2 may be a novel diagnostic and predictive biomarker for early-stage pancreatic cancer and pancreatic cancer development from IPMN, although a lower number of early-stage pancreatic cancer cases were evaluated in the test than in the validation cohort. Here, EPHA2 is linked to pancreatic intraductal papillary-mucinous neoplasm.